Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

(CAPTIVA-MRI Trial)

Recruiting at 12 trial locations

Overseen By Ka-Ho Wong, MBA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Yale University

Must be taking: Aspirin, Ticagrelor, Clopidogrel, Rivaroxaban

Disqualifiers: Pacemaker, Gadolinium allergy, Kidney disease, others

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 months

300 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPTIVA-MRI study leverages the CAPTIVA trial design and implementation to capture information that will inform and facilitate the next generation of ICAS trials and the management of patients with ICAS.

Who Is on the Research Team?

Rano Chatterjee, MD

Principal Investigator

Washington University School of Medicine

David Liebeskind, MD

Principal Investigator

University of California, Los Angeles

Sepideh Amin-Hanjani, MD

Principal Investigator

University Hospitals

Are You a Good Fit for This Trial?

Inclusion Criteria

Enrollment in the CAPTIVA trial: nondisabling symptomatic ischemic infarct stroke within 30 days secondary to 70-99% stenosis of the intracranial ICA, MCA, BA or VA

Ability to obtain baseline study MRI within 14 days of CAPTIVA enrollmen

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive aspirin plus ticagrelor, clopidogrel, or rivaroxaban

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

Group I: CAPTIVA-MRI Group Experimental Treatment 1 Intervention

CAPTIVA patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials

1,403

Recruited

655,000+